0001209191-21-011013.txt : 20210216 0001209191-21-011013.hdr.sgml : 20210216 20210216194605 ACCESSION NUMBER: 0001209191-21-011013 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210211 FILED AS OF DATE: 20210216 DATE AS OF CHANGE: 20210216 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Sauer Paul CENTRAL INDEX KEY: 0001813796 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-39323 FILM NUMBER: 21642017 MAIL ADDRESS: STREET 1: C/O VAXCYTE, INC. STREET 2: 353 HATCH DRIVE CITY: FOSTER CITY STATE: CA ZIP: 94404 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Vaxcyte, Inc. CENTRAL INDEX KEY: 0001649094 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 464233385 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 353 HATCH DR CITY: FOSTER CITY STATE: CA ZIP: 94404 BUSINESS PHONE: 650-837-0111 MAIL ADDRESS: STREET 1: 353 HATCH DR CITY: FOSTER CITY STATE: CA ZIP: 94404 FORMER COMPANY: FORMER CONFORMED NAME: SutroVax, Inc. DATE OF NAME CHANGE: 20150724 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-11 0 0001649094 Vaxcyte, Inc. PCVX 0001813796 Sauer Paul C/O VAXCYTE, INC. 353 HATCH DRIVE FOSTER CITY CA 94404 0 1 0 0 SVP Process Dev, Manufacturing Common Stock 2021-02-11 4 M 0 2500 1.79 A 80399 D Common Stock 2021-02-11 4 S 0 2184 26.56 D 78215 D Common Stock 2021-02-11 4 S 0 316 27.27 D 77899 D Stock Option (right to buy) 1.79 2021-02-11 4 M 0 2500 0.00 D 2027-05-17 Common Stock 2500 23926 D The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan. The price reported is a weighted-average price. The shares were sold at prices ranging from $25.97 to $26.96. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. The price reported is a weighted-average price. The shares were sold at prices ranging from $27.22 to $27.315. The reporting person will provide upon request to the SEC, the issuer or security holder of the issuer, full information regarding the number of shares sold at each separate price. 1/4 of the shares subject to the option vested on March 4, 2018, and 1/48 of the shares vest monthly thereafter. /s/ Winston Macaraeg, Attorney-in-Fact 2021-02-16